| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.EURURO.2018.03.030 |
| P698 | PubMed publication ID | 29678358 |
| P2093 | author name string | Chong Hyun Suh | |
| Sungmin Woo | |||
| Yeon Joo Kim | |||
| Sangwon Han | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| systematic review | Q1504425 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 179-190 | |
| P577 | publication date | 2018-04-18 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis | |
| P478 | volume | 74 |
| Q90163212 | (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer |
| Q92423926 | 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging |
| Q92375760 | 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial |
| Q89622356 | 68Ga-PSMA-11 PET accuracy in recurrent prostate cancer |
| Q89602349 | 68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact |
| Q93065017 | A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer |
| Q90259957 | A framework for the development of effective anti-metastatic agents |
| Q92671536 | Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial |
| Q92276001 | Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis |
| Q90306325 | Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse |
| Q60920500 | Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives |
| Q96128360 | Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET |
| Q93129302 | NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy |
| Q60938851 | New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen |
| Q89523006 | Otto: a 4.04 GBq (109 mCi) 68Ge/68Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [68Ga]Ga-PSMA-11 |
| Q58107966 | PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics |
| Q64230984 | Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics |
| Q90464069 | Practice changing for prostate cancer: a vision of the future |
| Q91152077 | Smart cancer nanomedicine |
| Q57107703 | Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine |
| Q93100308 | The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer |
| Q92224500 | The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer |
| Q102331397 | Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016) |
| Q91896910 | [Nuclear medicine for prostate cancer management] |
Search more.